Compare FedEx Corporation (FDX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Moderna, Inc. — how do they compare? FedEx Corporation trades at $316.44 (market cap $74.78B), while Moderna, Inc. trades at $65.23 (market cap $27.09B). The key difference: FedEx Corporation is far larger — about 2.8× Moderna, Inc.'s market cap, and FedEx Corporation pays a 1.56% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| FDX | MRNA | |
|---|---|---|
Market Cap | $74.78B | $27.09B |
Sector | Industrials | Health |
52-Week High | $338.75 | $81.80 |
52-Week Low | $174.81 | $22.36 |
Enterprise Value | $104.42B | $23.19B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $313.66, down slightly by 0.03% on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68%, and has beaten EPS estimates in recent quarters. Recent corporate actions include a dividend payment and a $1.4B sale of its supply chain unit to CMA CGM, aimed at streamlining operations.
The outlook for FDX is mixed; analyst consensus is bullish with a $360.27 price target, but technicals and margin pressures pose risks. Investment opportunities lie in cost-cutting initiatives and steady revenue growth, while risks include competitive threats from Amazon and soft shipping demand. The stock's valuation appears reasonable with a P/E of 16.9.
Moderna (MRNA) trades at $67.44, showing modest daily gains amid a bullish technical signal. The company continues to beat earnings expectations despite reporting significant net losses, with revenue declining from pandemic peaks to $1.92B in 2025. Recent positive developments include EU RSV vaccine contracts, Phase 1 cancer trial initiation, and FDA advisory panel support for its mRNA flu vaccine, driving recent stock momentum.
While Moderna's pipeline expansion beyond COVID-19 shows promise with oncology and rare disease applications, substantial financial risks persist with negative profit margins and cash burn. Analyst consensus remains cautious with a $49 price target below current levels, reflecting concerns about revenue sustainability versus pipeline execution risks and valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
